Literature DB >> 30824943

[Multidrug-resistant gram-negative rods in the intensive care unit : Epidemiology, prevention and treatment options].

G Valenza1.   

Abstract

In Germany, multidrug-resistant gram-negative rods (MRGN) are classified in two groups, namely those with resistance against three (3MRGN) and those with resistance against four (4MRGN) of the following antibiotic groups: acylureidopenicillins, third or fourth generation cephalosporins, fluoroquinolones and carbapenemes. The rate of 3MRGN enterobacteria and 4MRGN Pseudomonas aeruginosa has significantly increased in German intensive care units from 2008-2014. In contrast, 4MRGN enterobacteria are still rare. The 3MRGN and 4MRGN phenotypes can be associated with different antimicrobial resistance mechanisms such as the production of extended-spectrum β‑lactamases (ESBL) or carbapenemases. The strategy for the prevention and control of MRGN in intensive care units includes basic hygiene measures as well as special measures such as contact isolation of patients. The treatment of MRGN infections should be carried out according to the antimicrobial susceptibility test results.

Entities:  

Keywords:  Beta-lactamases; Carbapenem-resistant enterobacteriaceae; Epidemiology; Preventive medicine; Treatment

Mesh:

Substances:

Year:  2019        PMID: 30824943     DOI: 10.1007/s00063-019-0547-x

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  2 in total

1.  Bacterial Community and Genomic Analysis of Carbapenem-Resistant Acinetobacter baumannii Isolates from the Environment of a Health Care Facility in the Western Region of Saudi Arabia.

Authors:  Muhammad Yasir; Abdullah Mohammad Subahi; Hani A Shukri; Fehmida Bibi; Sayed Sartaj Sohrab; Maha Alawi; Anees A Sindi; Asif A Jiman-Fatani; Esam I Azhar
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-16

2.  [Screening for 4MRGN in German emergency departments].

Authors:  H Dormann; L Eichelsdörfer; M V Karg; H Mang; A-K Schumacher
Journal:  Med Klin Intensivmed Notfmed       Date:  2020-05-04       Impact factor: 0.840

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.